NCT03101748 2026-02-12
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
63 trialsNCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT02688803 2025-12-04
OTT15-04
Ottawa Hospital Research Institute
Phase 4 Terminated
NCT04958785 2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04251169 2025-06-03
TATEN
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT00520975 2025-03-28
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
Phase 3 Terminated
NCT03601897 2024-12-27
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT01897441 2024-12-24
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
Albert Einstein College of Medicine
Phase NA Terminated
NCT03498716 2024-08-21
IMpassion030
Hoffmann-La Roche
Phase 3 Terminated
NCT03393741 2024-06-25
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
Terminated
NCT00679029 2023-12-11
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Phase 2 Terminated
NCT01303679 2023-09-06
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 3 Terminated
NCT03329378 2023-08-22
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT00272987 2023-04-28
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Novartis
Phase 3 Terminated
NCT01147016 2023-04-27
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02322814 2023-04-13
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Hoffmann-La Roche
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT02474173 2022-11-04
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01779050 2022-11-01
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Washington University School of Medicine
Phase 2 Terminated
NCT01407562 2022-09-28
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT02824575 2022-04-04
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Montefiore Medical Center
Phase 1 Terminated
NCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT04031885 2021-08-24
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Eli Lilly and Company
Phase 4 Terminated
NCT00542191 2021-05-26
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Leo W. Jenkins Cancer Center
Phase 2 Terminated
NCT01220128 2021-05-25
INDUCT
GlaxoSmithKline
Phase 2 Terminated
NCT01495247 2020-12-08
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 1/2 Terminated
NCT01745367 2020-10-27
BATON-BC
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00622466 2020-10-19
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT00536939 2020-09-24
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT01697293 2020-09-24
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Prescient Therapeutics, Ltd.
Phase 1/2 Terminated
NCT01249443 2020-07-29
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
Phase 1 Terminated
NCT00003086 2020-07-14
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 1/2 Terminated
NCT02358200 2020-01-10
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
University of California, San Francisco
Phase 1 Terminated
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT01980277 2019-01-23
TAKTIC
Institut Paoli-Calmettes
Phase 1/2 Terminated
NCT02297230 2018-10-15
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
NYU Langone Health
Phase 1/2 Terminated
NCT02138812 2018-10-12
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Bayer
Phase 1 Terminated
NCT00088829 2018-07-11
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
Georgetown University
Phase 2 Terminated
NCT01009983 2018-07-06
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02379585 2018-04-24
STEFNE
Western Regional Medical Center
Phase 1/2 Terminated
NCT01512199 2017-10-18
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Daiichi Sankyo
Phase 1/2 Terminated
NCT00041470 2017-07-17
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
University of Washington
Phase 1/2 Terminated
NCT00194792 2017-07-11
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Phase 2 Terminated
NCT01120158 2017-02-23
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00537173 2017-01-25
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
Hoosier Cancer Research Network
Terminated
NCT01194869 2016-10-18
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
Emory University
Phase 2 Terminated
NCT01069796 2016-03-17
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 2 Terminated